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PURIFICATION OF SOLUBLE RECOMBINANT SALMONELLA TYPHIMURIUM FLAGELLIN
(FliC) PROTEIN CONSTRUCTS EXPRESSED IN ESCHERICHIA COLI

by

JENNIFER ANN HOOKER

Under the Direction of George E. Pierce

ABSTRACT
A platform for vaccine development has been developed at Georgia State University
utilizing recombinant Salmonella typhimurium flagellin (FliC) fused to an antigen that can
be overexpressed in Escherichia coli grown in a two‐stage fermentation. The flagellin acts
as an adjuvant to increase the immunopotency of the fused antigen. Flagellin is the ligand
for Toll‐like Receptor 5 (TLR5), a part of the innate immune system. Binding of the
flagellin:antigen recombinant protein to TLR5 triggers a strong innate and adaptive
immune response to the fused antigen leading to a potentially strong protective immunity
to the antigen.
Purification of the recombinant FliC fusion protein must meet rigorous criteria in
order to be used as a vaccine. One of the major issues in purifying recombinant proteins
expressed in a Gram‐negative bacterium is the removal of endotoxin. Small amounts of

endotoxin present in a vaccine can lead to serious complications, including death.
Recombinant proteins are also expressed as either soluble or insoluble protein when over
expressed in E. coli. Soluble proteins expressed by the bacterium are properly folded and
biologically active, however removal of contaminants such as endotoxin, can be
problematic. Insoluble protein is improperly folded and biologically inactive. The
insoluble proteins aggregate into inclusion bodies with little or no contaminants associated
with the protein, making purification easier. However, in order to restore the biological
activity of the insoluble protein, it must first be solubilized and then refolded. This process
is often expensive and time consuming, as there is currently no standardized method for
protein refolding.
In this study a purification method for the soluble protein of two FliC constructs,
full‐length FliC and FliC fused to a Marburg virus antigen, was evaluated for effectiveness in
purification, removal of endotoxin and maintaining TLR5 activity. The proteins of interest
were purified utilizing only the soluble protein containing the properly folded and
biologically active recombinant protein. Utilizing methods for purification that take
advantage of physical and chemical properties of the protein the recombinant proteins
were purified and the level of endotoxin reduced to levels acceptable for use as a vaccine.
The TLR5 activity of the soluble recombinant proteins was compared to recombinant
protein that had been purified using a denaturing and refolding step. The soluble protein
elicited a higher TLR5 response at a lower concentration of protein than the refolded
protein. Purification of the soluble fraction also involved fewer step and less time than
purification of both the soluble and insoluble protein.
INDEX WORDS: Flagellin, FliC, Toll‐like Receptor 5, Soluble Protein Purification,
Recombinant Protein
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1. INTRODUCTION
Conventional vaccines currently licensed for use in the United States typically
consist of: 1) attenuated whole cells 2) inactivated whole cells or 3) a purified antigenic
component of the microorganism. While vaccines presently in use have been successful
against a variety of pathogens, most require multiple doses to confer lasting immunity and
there are many diseases for which there is no vaccine available. Many vaccines or vaccine
candidates do not elicit a strong enough immune response when given alone to be effective
requiring the use of an adjuvant to increase the potency of the vaccine. The number of
adjuvants currently approved for use in vaccines is extremely limited due to side effects
that can be caused by the adjuvant and the stringent criteria required for licensing.
Currently, there are only two types of adjuvants licensed for use in vaccines in the United
States: alum, which is composed of aluminum salt or gel and AS04 (a combination of
aluminum hydroxide and monophosphoryl lipid A), which is only used in the Human
Papilloma virus (HPV) vaccine. Production of some vaccines can also be time consuming
and may not yield enough vaccine to meet demand. For example, influenza vaccine is
currently grown in eggs, with a production time of 6‐9 months and each egg yielding only
1‐3 doses of vaccine. Under the current method of production, it would be difficult to
redirect the production process for a pandemic or variant seasonal strain of influenza. An
ideal vaccine would be one that could be produced quickly and inexpensively, confers
lasting immunity and requires a single dose (Levine and Stein, 2004; Zinkernagel, 2003).
Advances in the understanding of the immune system response and genetic engineering
have led to new approaches in vaccine development. At Georgia State University (GSU), a
vaccine platform utilizing recombinant flagellin fused to a bacterial or viral antigen has
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been developed that can be efficiently overexpressed in E. coli grown in a large scale
fermentation and purified. The flagellin acts as an adjuvant significantly increasing the
immunopotency of the linked antigen (Huleatt et al., 2007; McDonald et al., 2008).
The human immune system is made up of two components: the innate immune
system and adaptive immune system. For a vaccine to confer lasting immunity, it must
induce a strong immune response in both the innate and adaptive immune systems. The
innate immune system comprises the “first response” to an infectious agent. Once a
pathogen is detected, the innate immune system launches a non‐specific response utilizing
interferon, complement, natural killer cells and activated phagocytes in an attempt to clear
the infection. Antigen presenting cells (APCs), a component of the innate immune system,
link the innate and adaptive immune system. Antigen from the pathogen is processed by
the APCs and presented to the adaptive immune system that is composed of B‐ and T‐ cells.
Once presented with antigen, the B‐ and T‐cells become activated. Activated B‐cells secrete
antibodies that are specific to the antigen and T‐cells directly attack the pathogen to clear
the infection. A subset of these activated B‐ and T‐ cells become “memory” cells. When
presented with an antigen the adaptive immune system has previously been exposed to,
the immune system is able to launch an antigen specific response using these memory cells,
resulting in a faster and more effective immune response. An effective vaccine must create
protective immunity by inducing production of memory cells (immunological memory), a
process that is in part activated by the innate immune response.
The innate immune systems of both vertebrates and invertebrates have developed a
strategy to detect microbial infection using Toll‐like receptors (TLRs) that recognize highly
conserved regions of pathogens that are unique to microorganisms. TLRs are a member of
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the Interleukin‐1 receptor/Toll‐like receptor superfamily based upon homology of the Toll‐
interleukin (IL)‐1 receptor domain (TIR). TLRs are trans‐membrane proteins that function
as homo‐ or hetero‐dimers with three functional domains: an extra‐cellular leucine‐rich
repeat (LRR), a membrane spanning portion and an intracellular TIR. The extracellular
LRR forms a horseshoe shape that is believed to function in the recognition of a specific
microbial motif. The TIR is required for activation of the signal cascade leading to an
innate immune response (Akira and Takeda, 2004). Recognition of a specific conserved
microbial motif or pathogen‐associated molecular pattern (PAMP) by the associated TLR
receptor induces a signaling cascade resulting in a non‐specific immune response to the
pathogen. TLRs have also been shown to play a fundamental role in the induction of the
adaptive immune response (Medzhitov et al., 1997; Schnare et al., 2001). There are
currently 10 known TLRs expressed in humans that recognize a specific ligand (Table 1).
This study focuses on Toll‐like receptor 5 (TLR5) and its ligand, flagellin. TLR5 specifically
recognizes the protein, bacterial flagellin, and is the only TLR known, to date that
exclusively recognizes a single type of protein.
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Table 1. Human Toll‐like Receptors and their ligands (Akira, 2011; Medzhitov, 2001)
Toll‐like Receptor
TLR1/TLR2
TLR2
TLR3
TLR4
TLR5
TLR6/TLR2
TLR7
TLR8
TLR9
TLR10

TLR ligand
Bacterial lipopeptide
Gram‐positive lipoproteins, lipomannans and lipotechoic
acids
Viral double stranded RNA
Lipopolysaccharide
Bacterial flagellin
Mycoplasmal macrophage‐activating lipopeptide
2kDA(MALP‐2)
Small synthetic antiviral molecules, single stranded RNA
Small synthetic antiviral molecules, single stranded RNA
Unmethylated CpG DNA
unknown
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The TLR5 ligand, flagellin, is the protein monomer that makes up a bacterial
flagellum. Each flagellin monomer is composed of four domains: D0, D1, D2 and D3
(Figure 1). The D0 and D1 domains consist of the N‐terminal and C‐terminal regions and
are the most highly conserved regions of flagellin. These two domains make up the
flagellar filament backbone and are critical for flagellar filament assembly (Kuwajima,
1998)(Figure 2). A mutation in this region would be detrimental to the microorganism by
affecting motility and possibly virulence. Research has shown that a specific region in the
conserved D1 domain interacts directly with TLR5 (Eaves‐Pyles et al., 2001; Smith et al.,
2003). The D2 and D3 region of flagellin comprise the exposed part of the flagellum
filament and are highly variable. These regions are responsible for the antigenicity of
flagellin (Yoshioka et al., 1995; He et al., 1993). Binding of flagellin to TLR5 induces a
MyD88‐dependent signaling cascade leading to activation of the transcription factor NF‐κB
that in turn activates the innate immune system against a flagellated bacterium and
ultimately the adaptive immune system via dendritic cells (Didierlaurent et al., 2004)
(Figure 3).
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Figure 1. Domains of flagellin monomer, FliC, from S.
typhimurium (Cruz Ramos, et al, 2004).

Figure 2. Orientation of flagellin monomer domains in bacterial flagellum.
a) flagellum filament as seen from the top b) Flagellum filament viewed
from the side (Yonekura, et al, 2003).
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Figure 3. Signaling cascade induced by the binding of flagellin
monomer to human Toll‐like receptor 5 (Cruz Ramos, et al, 2004).
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Toll‐like receptor 5 is expressed by dendritic cells (DCs), a class of antigen
presenting cells in humans that are present in the nose, lungs, stomach and intestines.
Binding of flagellin to the TLR5 receptor present on dendritic cells results in the activation
and maturation of the DC. The DC processes the flagellin and the linked antigen and
presents both to B‐ and T‐ cells present in the lymph nodes, resulting in the activation of
both naïve T‐cells and B‐cells, components of the adaptive immune system (Figure 4).
Activation of DCs via TLR5 serves as an important link between the innate and adaptive
immune (Iwasaki and Medzhitov, 2004; Means et al., 2003).
The use of flagellin as an adjuvant in vaccines has been shown to greatly increase
the immunopotency of an antigen particularly when that antigen is linked to flagellin
resulting in activation of both the innate and adaptive immune systems (Huleatt, et al,
2007). By linking an antigen to flagellin, the vaccine takes advantage of a system already
present in the innate immune system, inducing a faster and stronger adaptive immune
response to an antigen that may have elicited a weak or no immune response. Previous
exposure of flagellin to the immune system has not been shown to decrease its
effectiveness as an adjuvant allowing it to potentially be used in multiple vaccines and is
effective at eliciting a strong immune response at very low doses (Honko et al., 2006; Ben‐
Yedidia and Arnon, 1998).
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Figure 4. Schematic of dendritic cell activation through binding of flagellin to TLR5
receptor
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The recombinant proteins to be discussed were constructed using the DNA
sequence for the flagellin protein, fliC, from Salmonella typhimurium LT2, which was cloned
into Escherichia coli for expression and protein production. There are several potential
insertion sites for antigen in FliC. The insertion sites least likely to affect TLR5 recognition
include the N‐terminal D0 region, the hypervariable D2‐D3 region, and the C‐terminal D0
region of FliC, with the latter two being the best potential insertion sites (Figure 5).
Insertion of an antigen into the N‐terminal D0 region is possible, specifically amino acids 1‐
78, but might require a start codon to be engineered into DNA sequence of the antigen.
Research has shown that deletion or insertion of other amino acid sequences into the
hypervariable region has had little or no effect on recognition of FliC by TLR5 (Eaves‐Pyles
et al., 2001). However, the size of the inserted antigen is restricted by the size of the
deletion in the D3 region. Insertion of an antigen that is too large for the D3 region might
affect the folding of the protein and TLR5 recognition. Because the hypervariable region of
FliC is the antigenic region recognized by the human immune system, a benefit of deleting
this region is that it would allow the vaccine construct to possibly evade neutralizing
antibodies that may decrease the effectiveness of the vaccine (Nempont et al., 2008).
Insertion of an antigen into the N‐terminal and C‐terminal D1 regions, specifically amino
acids 78‐129, 135‐173 and 395‐444, should be avoided. Insertion of antigen into these
regions has been show to disrupt TLR5 recognition of FliC (Smith et al., 2003).
To date, two S. typhimurium FliC constructs have been developed and successfully
overexpressed in E. coli grown in a two‐stage fermentation at Georgia State University
(GSU), a full‐length FliC recombinant protein (FA4000) and a FliC:GP132 recombinant
protein (5088) with GP132 fused to the C‐terminal end of a FliC flagellin truncated by
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approximately 30 amino acids. GP132 is a truncated glycoprotein from Marburg virus that
has been shown to induce protective immunity in mice (Kalina, et al, 2009). Expression of
recombinant proteins in E. coli is a highly effective and inexpensive way to quickly produce
large quantities of recombinant protein for use as a vaccine. However, the use of Gram‐
negative bacteria as a host for recombinant protein expression creates some problems in
purification of a protein to be used as a vaccine.
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Figure 5. Linearized FliC protein with labeled regions and corresponding amino acid
sequence. (ND0‐ N‐terminal D0, ND1 – N‐terminal D1, CD1 – C‐terminal D1 and
CD0 – C‐terminal D0.) Blue areas indicates where antigen insertion is possible and
red areas indicates where antigen should not be inserted into FliC. (Smith et al,
2003; Samatey et al., 2001 and Yonekura et al., 2003.)
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One of the major problems encountered when using a Gram‐negative bacterium as a
host for expression of a recombinant protein is the presence of significant amounts of
endotoxin (ET). Endotoxin is the lipopolysaccharide (LPS) present in the outer membrane
of the cell wall in Gram‐negative bacteria (Figure 6). ET is a very stable molecule, able to
withstand high temperatures and variations in pH. ET also binds to protein with certain
proteins having a significantly higher affinity for endotoxin making it difficult to remove
from protein preparations. The presence of even a small amount of endotoxin in a
recombinant protein vaccine can cause serious side effects such as, a systemic
inflammatory reaction that can lead to shock, tissue injury and possibly death. A very
small amount of endotoxin is capable of causing side effects, so the removal of endotoxin
from protein to be used as a vaccine is crucial (Magalhães et al., 2007). The Federal Drug
Administration has established the acceptable endotoxin level in vaccines as 5 endotoxin
units (EU)/kg of bodyweight. Additionally, endotoxin has been shown to interfere with a
number of in vitro assays, including the TLR5 assay used to determine the biological
activity of flagellin (Liu et al., 1997).
Another issue stemming from overexpression of recombinant protein in Gram‐
negative bacteria is how the protein is expressed when expression of a protein is over‐
induced. Recombinant proteins overexpressed in E. coli can be expressed as either soluble
or insoluble protein (Figure 6) requiring several different approaches to purification
depending on how the protein is expressed in order to optimize the protein yield.
Recombinant proteins expressed as soluble protein have a higher percentage of properly
folded protein and biologically active molecules, but more contaminants, including
endotoxin, which must be removed during purification. Insoluble protein can often
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account for over 50% of the expressed protein and these misfolded and/or incompletely
folded, inactive proteins aggregate into inclusion bodies (IB). Inclusion body formation is
often exacerbated by the over‐expression of the recombinant protein in E. coli that can lead
to an insufficient amount of chaperones in the cell to assist in proper protein folding and
competition between protein folding and aggregation (Basu et al., 2011; Georgiou and
Valax, 1996). In order to recover the native protein from inclusion bodies, the protein must
first be solubilized and then refolded into its proper, biologically active conformation. This
step poses a significant problem during purification because there is currently no
standardized method for refolding protein and optimal refolding conditions must be
determined for each individual recombinant protein construct. The typical yield of
bioactive protein following protein refolding is also low, ranging from 15‐40%. The low
yield of biologically active protein is primarily due to protein aggregation during refolding
(Singh and Panda, 2005; Yang et al., 2011). Over all, this process can be extremely time
consuming and costly. However, because these proteins are contained in inclusion bodies
the level of contaminants, especially endotoxin, is much lower than in the soluble fraction
and often requires fewer steps for purification. GSU recombinant FliC protein constructs
FA4000 and 5088 expressed primarily as soluble protein during fermentation, with some
expression as insoluble protein (Figures 7 and 8).
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Figure 6. Diagram of the chemical structure of
lipopolysaccharide from E. coli (Magalhães et al.,
2007).
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Figure 7. Schematic of soluble and insoluble protein formation when
recombinant proteins are overexpressed in E. coli. (Middleberg, 2002).
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Figure 8. SDS‐PAGE of soluble and insoluble protein fractions from
fermentation samples before and after induction of recombinant FA4000
protein. The highlighted area indicates the location of the FA4000 protein and
the arrows indicate the location of pre‐induction soluble FA4000 (lane 3) and
4h post‐induction soluble FA4000 (lane 6).
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Figure 9. SDS‐PAGE of soluble and insoluble protein fractions from fermentation
samples before and after induction of recombinant 5800 protein. The highlighted area
indicates the location of the recombinant 5088 protein and the arrows indicate the
location of pre‐induction soluble 5088 (lane 3), 1h post‐induction soluble 5088 (lane 6),
2h post‐induction soluble 5088 (lane 9) and 3h post‐induction soluble 5088 (lane12).
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In the past, two purification schemes have been used at Georgia State University
(Figure 10). The purification scheme used was dependent upon how the recombinant
protein was expressed during fermentation. Both purifications began with homogenization
to lyse the cells and an initial centrifugation step to remove cell debris. Following
centrifugation, soluble protein present in the supernatant was purified using purification
scheme A and insoluble protein present in the pellet was purified using purification scheme
B. Because the recombinant FliC protein constructs in this study were expressed primarily
as soluble protein only purification scheme A will be discussed. Purification scheme A was
designed for protein expressed largely in the soluble fraction, but in order to optimize the
protein yield it also incorporated steps to solubilize any insoluble protein still present in
the supernatant. Each step in the purification was designed to remove one or more
impurities using the physical and chemical properties of the recombinant protein and the
methods chosen for purification are well‐established techniques that can be easily and cost
effectively scaled up for industrial scale production.
Polyethylene Glycol 3350 (PEG 3350) was chosen for protein precipitation. PEG
3350 is a parenthetical chemical widely used in chemical and biomedical applications and
is non‐denaturing, therefore maintaining the native structure of the protein and its
biological activity. PEG 3350 also effectively precipitates protein at a low concentration,
typically less than a 20% concentration of PEG 3350. The mechanism behind polyethylene
glycol (PEG) precipitation is not well understood, but is thought to surround the protein
causing it to precipitate from solution (Atha and Ingram, 1981). Application of PEG
precipitation remains empirical, so each new recombinant FliC fusion protein will likely
require optimization of PEG 3350 precipitation. Following the PEG precipitation, the
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proteins were resuspended in a denaturing 8M urea buffer to recover the insoluble protein
present in the cell lysate. While this allows the recovery of insoluble protein, it also
denatures the already biologically active soluble protein present and necessitated the
addition of several steps to the purification process: tangential flow filtration and a
solubilization and refolding step.
A buffer exchange step using tangential flow filtration (TFF) was used to remove the
denaturing agent present in the sample prior to the two‐phase separation. TFF, or cross
flow filtration, can be used to process large volumes of sample and involves the use of a
membrane with a specific molecular weight cut‐off. The sample was pumped against the
membrane and filtration was achieved by creating pressure against the membrane pushing
solute and smaller molecules through the membrane in the filtrate. The larger molecules,
including the recombinant protein, that were not pushed through the membrane were
collected in the retentate. During the filtration process, a non‐denaturing buffer was
continually added to the retentate in order to achieve a buffer exchange. Because the
denaturing agent was removed during the buffer exchange, the protein refolded and must
be denatured following the two‐phase separation and then refolded again under controlled
conditions to promote refolding into the proper biologically active conformation.
A two‐phase separation using the surfactant, Triton® X‐114, was used following the
buffer exchange in order to remove endotoxin from the recombinant protein. Two‐phase
separation was chosen because it is a cost‐effective method and has been shown
successfully remove endotoxin from recombinant protein solutions (Aida and Pabst, 1990;
Liu et al., 1997). Upon addition of Triton X®‐114 at a temperature below 22°C, the cloud
point for Triton X®‐114, ET disassociates from the protein in a homogeneous solution.
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When the temperature is raised above 22°C, the solution separates into 2‐phases, an
aqueous phase containing the recombinant protein and a micelle rich detergent phase
containing the endotoxin (Figure 11). The aqueous and detergent phase were separated
using centrifugation at a temperature above the cloud point.
The final steps in the purification included anion exchange chromatography (AEX)
and hydrophobic interaction chromatography (HIC). AEX separates protein based on its
net surface charge. Proteins in a solution with a pH higher than their isoelectric point (pI)
have a negative charge, allowing the protein to bind reversibly to positively charged media
in the AEX column. The bound protein is eluted by changing the ionic strength (salt
concentration) of the buffer running through the column. This step was used to separate
the recombinant protein from other proteins remaining as well as removing any residual
Triton X®‐114 or impurities still present. HIC was used as a polishing step when necessary
to remove any remaining impurities. HIC separates proteins based on their surface
hydrophobicity. The salt concentration of the solution containing the recombinant protein
is increased prior to HIC to enhance the interaction of the hydrophobic components of the
protein with the media in the HIC column. The proteins bind reversibly to the media in the
column and are eluted from the column by decreasing the ionic strength (salt
concentration) of the running buffer.
Once the recombinant FliC fusion protein was purified it was tested for TLR5
activity using modified Human Embryonic Kidney (HEK) 293 cells. Commercially available
HEK‐Blue™ hTLR5 cells (InvivoGen, San Diego, CA) (hTRL5 cells) were co‐transfected with
a human TLR5 (hTLR5) gene and secreted embryonic alkaline phosphatase (SEAP) gene
under the control of a NF‐κB promoter. Stimulation of hTLR5 by its ligand, flagellin,
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activates the NF‐κB promoter inducing production of SEAP. The level of TLR5 activation
was measured by detecting the amount of SEAP present due to the stimulation of hTLR5
through a color change. HEK‐Blue™ Null I cells (InvivoGen, San Diego, CA) (null cells) are
the parental cell line for the HEK‐Blue™ hTLR5 cells and were used in the assay to
determine the baseline level of TLR5 activity in the cells. The TLR5 assay determined if the
fusion protein was capable of inducing an immune response via binding to TLR5. The
recombinant protein must exhibit a strong TLR5 response if it is to be used as a vaccine.
Low or no TLR5 activity might indicate that the recombinant protein does not have the
proper conformation needed to induce a TLR5 response and the construct needs to be
reevaluated.

23

1.1. Rationale and Hypothesis
GSU does not have a purification scheme designed to purify only the recombinant
flagellin (FliC) proteins expressed as soluble protein. Purification of the soluble
recombinant protein would hypothetically reduce the number of steps presently used in
purification scheme A, as well as the time and cost needed for purification. By purifying the
soluble protein the denaturing step following the PEG precipitation would be eliminated,
which would also allow the removal of the buffer exchange via TFF, denaturing step
following the two‐phase separation and the refolding step. Currently, there is no standard
protocol for refolding proteins and this process alone can account for a major portion of
production costs (Datar et al., 1993). The protein would also remain in its native,
biologically active form throughout the purification process and it is hypothesized that the
soluble recombinant flagellin protein should have a higher TLR5 activity than recombinant
protein that has been refolded. The recombinant proteins previously purified at GSU using
either purification scheme A or B have exhibited TLR5 activity at a lower level than a
commercially available recombinant FliC standard and the amount of recombinant protein
necessary to elicit a comparable TLR5 response has been significantly higher than the FliC
standard. A purification strategy designed for the soluble fraction of recombinant
proteins FA4000 and 5088 could also potentially be applicable to future Salmonella
typhimurium FliC vaccine fusion proteins.
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Figure 10. Schematic of Applied and Environmental Microbiology (GSU)
Purification Processes for A) Purification process for both soluble and insoluble
protein and B) Purification process for insoluble protein.
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Figure 11. Illustration of formation of phase separation in Triton detergents above
their cloud point. For Triton X‐114, the two phases form above the cloud‐point
temperature of 22°C, allowing separation of the protein and endotoxin.
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2. MATERIALS AND METHODS
2.1. Homogenization of Cell Paste
The same homogenization method was used for both FA400 and 5088 FliC
recombinant proteins. The cells harvested from the fermentor was stored at ‐80°C in 150g
aliquots. Prior to homogenization, the cell paste was removed from ‐80°C and allowed to
thaw overnight at 4°C. The weight of the cell paste was used to calculate the amount of
Lysis Buffer (20mM Tris, 100mM NaCl, 1mM EDTA, 100mM sucrose, pH 8) to add, with the
volume of lysis buffer added equal to 15% solids. The thawed cell paste and lysis buffer
were placed in an appropriate container with a stir bar and allowed to stir for > 30 minutes
on ice. To prepare the APV®‐1000 homogenizer (APV® Delavan, WI) for the sample, cold
ddH2O was run continuously through the homogenizer for 10 minutes, followed by cold
lysis buffer for another 5‐10 minutes. The resuspended cell paste was sampled and then
poured into the hopper on the homogenizer and passed through the homogenizer at 0 bar
into an appropriate sized container in an ice bath containing ice and isopropyl alcohol. The
cell paste was then passed through the homogenizer 3 more times at 690bar. The
temperature of the cell lysate was monitored after each pass through the homogenizer to
ensure the temperature remained below 25°C and allowed to cool to 5°C before passing
through the homogenizer again. After the final pass, the cell lysate was collected, the
volume measured, sampled and either stored at 4°C or further processed.
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2.2. Partial Clarification and Polyethylene Glycol 3350 Protein Precipitation
The cell lysate was centrifuged for 30 minutes at 4°C, 10,000rpm to remove cell
debris. The supernatant was poured off, the volume measured and retained for further
processing. The pellet was weighed, resuspended in an 8M urea buffer equal to the
volume of the supernatant, sampled for analysis and discarded once testing was completed
and showed no significant loss of the target protein. In order to precipitate the protein of
interest, a 4% concentration of PEG 3350 was added to the supernatant collected from the
centrifugation step above. The PEG 3350 was added slowly to the supernatant while
stirring. After all the PEG 3350 dissolved, the supernatant was allowed to stir for ≥ 20
minutes. The solution containing the precipitated recombinant proteins was centrifuged
for 1 hour at 4°C, 10,000rpm. (Following this step, the PEG 3350 pellets can be frozen at
‐20C to be processed at a later date.) After centrifugation, the supernatant was pooled and
sampled, the volume measured and then discarded. The pellet was resuspended in
Resuspension Buffer (20mM tris, 1mM EDTA, 100mM sucrose, pH8) equal to ½ the volume
of the supernatant and stirred for ≥ 30 minutes until the pellet was completely
resuspended. After sampling the resuspended PEG 3350 pellet, the pellet was centrifuged
for 1 hour at 4°C, 10,000rpm. The resulting pellets were pooled, weighed, resuspended in
an 8M urea buffer equal to the volume of the supernatant, sampled and then discarded.
The supernatant or refined lysate (RL) was pooled and further processed using two‐phase
separation and hydrophobic interaction chromatography (HIC) or stored at 4°C.
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2.3. Twophase separation
1% (w/w) Triton® X‐114 was added to the RL and stirred for ≥ 30 minutes at room
temperature. The RL was centrifuged for 4 hours at 24°C, 10,000 rpm with the centrifuge
brake off and left overnight. Following centrifugation the top layer or aqueous phase (AP)
was carefully removed using a pipet, pooled, sampled and filtered using a 0.2µm
polyethersulfone (PES) syringe filter and either stored at 4°C or further processed. The
detergent phase (DP) was pooled, sampled and discarded.

2.4. Hydrophobic Interaction Chromatography
The filtered aqueous phase (FAP) was diluted to 2.5M NaCl with a 1:1 dilution of 5M
sodium chloride (NaCl) to FAP and stirred for 10 minutes. Prior to loading the FAP on a
5ml Toyopearl® PPG‐600 HIC column (Tosoh Bioscience, King of Prussia, PA), the sample
was filtered using a 0.2µm PES syringe filter and the protein was diluted to 0.1mg/ml total
protein with 2.5M NaCl. Column chromatography was performed using the
ÄKTAexplorer™100 system. (GE Lifesciences, Piscataway, NJ) The column was equilibrated
for 5 column volumes (CV) with equilibration buffer (2.5M NaCl, 20mM tris, pH 8).
Following equilibration 10 milligrams of diluted FAP was loaded onto the column using the
sample pump, P‐960 and washed with 2CV of equilibration buffer (2.5M NaCl, 20mM tris,
pH 8) to remove any unbound protein. During the previous two steps, the load flow
through and post load wash were collected separately for testing. Bound protein was
eluted by decreasing the salt concentration using a step elution of 25%, 50%, 75% and

29

100% 20mM tris, pH8. The eluate was collected using a Fraction Collector Frac‐950 (GE
Lifesciences, Piscataway, NJ) in 5ml fractions and the fractions corresponding to each peak
were collected for further processing and testing.

2.5. Sample Desalting
Following HIC, the samples were desalted using a HiPrep™ 26/10 desalting column
and ÄKTAexplorer™100 system (GE Lifesciences, Piscataway, NJ) or a 10ml Dextran
desalting column (Thermo Scientific, Rockford, IL) depending on sample size. The columns
were equilibrated with 5 CV of 20mM tris, pH 8. Following the column equilibration, the
sample was loaded via sample pump, P‐960 when using the HiPrep™ 26/10 desalting
column or via pipet for the 10ml dextran desalting column. The protein was eluted with
1‐2 CV 20mM tris and the eluate was collected using a Fraction Collector Frac‐950 (GE
Lifesciences, Piscataway, NJ) in 5ml fractions for the HiPrep™ 26/10 desalting column.
Eluate from the 10ml dextran desalting column were collected manually in 0.5ml fractions.

2.6. SDSPAGE Gel Electrophoresis
Running buffer for gel electrophoresis was prepared by adding 50ml of 20X
NuPAGE® MOPS Running Buffer (Invitrogen, Grand Island, NY) to 950ml ddH2O for a 1X
MOPS Running Buffer. (Running buffer should be prepared the day prior to running the
gel, so the running buffer can be chilled to 4°C. This helps to dissipate the heat generated
when the gel is being run.) The samples to be imaged were prepared for SDS‐PAGE
electrophoresis by adding 5µg of sample protein to 10µl NuPAGE® LDS Sample Buffer
(Invitrogen, Grand Island, NY) and ddH20 up to 40µl in a 1.5ml micro‐centrifuge tube.
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For samples with a protein concentration lower than 0.6mg/ml, 30µl of sample and 10µl
NuPAGE® LDS Sample Buffer (Invitrogen, Grand Island, NY) was used. The samples
were incubated for 10 minutes at 70°C and allowed to cool. Prior to loading the samples 1X
MOPS running buffer was added to the upper chamber so that the wells in the gel are filled
with buffer and to determine that there was no buffer leaking from the upper buffer
chamber. 10µl of each sample was loaded into a 15 well NuPAGE® Novex 4‐12% Bis‐Tris
Gel (Invitrogen, Grand Island, NY) and 5µl of MWM added to at least one well. Once the
samples were loaded 1X MOPS running buffer (~600ml) was added to the outer buffer
chamber. The SDS‐PAGE gels were run in the Xcell Surelock® Mini‐Cell (Invitrogen, Grand
Island, NY) at 200V for 1 hour.

2.7. Coomassie Blue Staining
A stain of 1% Coomassie® Brilliant Blue G‐250 (Sigma) was prepared and filtered
prior to use. The SDS‐PAGE gels containing sample were stained for a minimum of 3 hours
to overnight. Following staining, the gels were destained using ddH2O until the protein
bands were visible and the gel able to be imaged.
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2.8. Kinetic –QCL Endotoxin Assay
The endotoxin level of each sample was determined using the Lonza QCL‐kinetic
chromogenic kit® (Lonza, Allendale, NJ), which detects Gram‐negative bacterial endotoxin.
The samples were pre‐diluted using limulus amebocyte lysate (LAL) reagent water to a
lower concentration in order to fit into the range of the standard curve. The dilution was
dependent on which stage of purification the sample was collected. The standard for the
assay was an E. coli control standard endotoxin (CSE) that was rehydrated with a pre‐
determined amount of LAL reagent water indicated on the certificate of analysis to yield a
concentration of 50EU/ml. Prior to diluting the CSE, it was incubated at room temperature
for 15 minutes and then vortexed for 15 minutes. The CSE was diluted using LAL reagent
water to several concentrations in order to generate a standard curve. (Table 2) The
samples were also diluted to several concentrations in order to fit within the standard
curve and determine the endotoxin concentration of each sample (Table 3).
Table 2. E. coli control standard endotoxin dilutions for LAL endotoxin assay
Dilution
Sample Volume(µL)
Diluent (µL)
Total Volume(µL)
1:5
80
320
400
1:25
80 of 1:5
320
400
1:125
80 of 1:25
320
400
1:625
80 of 1:125
320
400

Table 3. Sample dilutions for LAL endotoxin assay
Dilution
1:5
1:50
1:500
1:5000

CSE Volume (µL)
80
50 of 1:5
50 of 1:50
50 of 1: 500

Diluent (µL)
320
450
450
450

Total Volume( µL)
400
500
500
500
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Each CSE and sample dilution was vortexed for ~ 1 minute between each serial dilution
and vortexed again before it was added to a 96‐well microplate. Following addition of the
samples, the microplate was pre‐incubated for 10 minutes at 37°C prior to adding the LAL
reagent. Before the 10‐minute pre‐incubation was over the LAL regent was rehydrated
with 2.6ml LAL reagent water and shaken until fully dissolved. The rehydrated LAL
reagent was added to a pyrogen‐free reservoir. Following the 10 minute incubation of the
microplate, 100 µL of the LAL reagent was added to each well containing sample using a
multichannel pipette. (It is important that there are no bubbles are present in the plate
wells.) The plate was loaded into the SpectraMax® Plus Microplate Reader (Molecular
Devices, Sunnyvale, CA) and absorbance (405nm) was read every 2½ minutes at 37°C until
the absorbance increased 0.200 absorbance units from the first reading. The data was
collected and analyzed using SoftMax® Pro software (Molecular Devices, Sunnyvale, CA)
and a standard curve was generated with a log‐log curve. The correlation coefficient (r)
should be ≥ 0.980 in order to construct the standard curve and predict the sample
endotoxin concentration (x). The x value for each sample is then multiplied by their
respective dilution factor to obtain the total amount of endotoxin for each sample.
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2.9. Maintenance of HEKBlue™ hTLR5 and HEKBlue™ Null I cells
2.9.1. Reviving HEKBlue™ hTLR5 and HEKBlue™ Null I cells
Both HEK‐Blue™ hTLR5 (hTLR5) and HEK‐Blue™ Null I (null) cells were stored in
1ml aliquots in cryovials in liquid nitrogen prior to use. To start a new culture for testing, a
vial of each type of cell was removed from liquid nitrogen and placed in a 37°C water bath
to thaw. Two T75 flasks (Corning, Tewksbury, MA) for each type of HEK cell were filled
with 11.5ml of growth media (DMEM w/ 4.5 g/l glucose, 10% (v/v) fetal bovine serum, 50
U/ml penicillin, 50 µg/ml streptomycin, 100 µg/ml Normocin™, 2mM L‐glutamine)
previously warmed to 37°C in a water bath. 0.5ml of thawed cells were added to the
growth media in the flasks and gently swirled. The flasks were placed in a 37°C, 5% CO2
incubator. The cells were allowed to grow until they were 70‐80% confluent before
passaging the cells to new T75 flasks. The cells were passaged twice after removal from
storage before the growth media was supplemented with Blasticidin (30 µg/ml) and
Zeocin™ (100 µg/ml) for hTLR5 cells and Zeocin™ (100 µg/ml) for the null cells. The
growth media was changed twice a week.

2.9.2. Passaging HEKBlue™ hTLR5 and HEKBlue™ Null I cells
Cells were passaged when growth was 70‐80% confluent. The spent media was
removed and the cells were washed with 5ml 1X phosphate buffered saline (PBS) (Corning,
Tewksbury, MA). The PBS was removed using a pipet and another 5ml 1X PBS added to the
flask to resuspend the cells. The cells were removed from the flask wall by gently tapping
the flask. Once the cells had been removed from the flask wall, the cells were pipetted up
and down to separate the cells from each other. Two T75 flasks (Corning, Tewksbury, MA)
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for each cell were filled with 11.5ml of growth media (hTLR5 ‐ DMEM w/ 4.5 g/l glucose,
10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin, 100 µg/ml
Normocin™, 2mM L‐glutamine, 30 µg/ml Blasticidin, 100 µg/ml Zeocin™ and null ‐ DMEM
w/ 4.5 g/l glucose, 10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 µg/ml
streptomycin, 100 µg/ml Normocin™, 2mM L‐glutamine, 100 µg/ml Zeocin™) warmed to
37°C. 0.5ml of resuspended cells were added to the growth media in the flasks and gently
swirled. The flasks were placed in a 37°C, 5% CO2 incubator.

2.10. TLR5 Activity Assay
Using HEK‐Blue™ hTLR5 cells (InvivoGen, San Diego, CA) (hTRL5 cells) stimulation
of TLR5 by its ligand, flagellin, was determined by measuring changes in color. HEK‐Blue
hTLR5 cells were co‐transfected with a human TLR5 (hTLR5) gene and secreted embryonic
alkaline phosphatase (SEAP) gene under the control of a NF‐κB promoter. Stimulation of
hTLR5 activates the NF‐κB promoter inducing production of SEAP. QUANTI‐Blue™
(InvivoGen, San Diego, CA) was used to detect the amount of alkaline phosphatase present
due to the stimulation of hTLR5. Color changes were measured by OD630. Recombinant
Salmonella typhimurium flagellin or FliC (InvivoGen, San Diego, CA) was used as the
positive control and endotoxin free water as a negative control. HEK‐Blue™ Null I cells
(InvivoGen, San Diego, CA) (null cells) are the parental cell line for the HEK‐Blue™ hTLR5
cells and were used in the assay to determine the baseline level of TLR5 activity in the cells.
Both the hTLR5 and null cells were harvested from T75 tissue culture flasks
(Corning®, Tewksbury, MA) with 5‐10ml 1x PBS (Corning cellgro®, Tewksbury, MA).
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The cells were diluted with a 0.4% trypan blue solution (Sigma‐Aldrich®, St. Louis, MO)
and counted using a Neubauer hemocytometer. Once the total number of cells/ml was
calculated, the cells were diluted with test media (DMEM, 4.5g/l glucose, 50U/ml penicillin,
50µg/ml streptomycin, 100µg/ml Normocin™, 2mM L‐glutamine, 10% (v/v) heat‐
inactivated fetal bovine serum) to a concentration of 140,000 cells/ml. 20µl of each sample
in triplicate, as well as the positive control and negative control were added to a 96 well
plate. 180µl of the above cell suspension was added to each well with sample. The plate
was incubated at 37°C, 5% CO2 for 20‐24 hours. Following incubation, 20µl of supernatant
from each sample was added to a new well and 180µl of QUANTI‐Blue™ was added to the
supernatant. The plate was incubated for 1‐3 hours at 37°C. After incubation the
absorbance of each well was read at 630nm with a Victor™ Plate Reader (PerkinElmer,
Waltham, MA). To determine the level of TLR5 activity, the OD630 sample reading of the
HEK‐Blue™ Null I cells was subtracted from the OD630 reading of the HEK‐Blue™ hTLR5
cells to determine the accurate TLR5 activity for each sample.

2.11. Western Blot
The samples for Western Blotting were run on an SDS‐PAGE gel with the Magic
Mark™ XP Western Protein Standard (Invitrogen, Grand Island, NY) using the same
protocol for SDS‐PAGE gel electrophoresis. The gel was placed in water after it had
finished running. The blotting pads were soaked in 700ml of transfer buffer until saturated
and then pressed until all the air bubbles were removed. A pre‐cut nitrocellulose blotting
membrane, 0.45µm pore size and filters (Invitrogen, Grand Island, NY) were briefly soaked
in transfer buffer prior to putting together the blotting “sandwich” (Figure 11). The
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transfer was performed using the Xcell II™ Blot Module (Invitrogen, Grand Island, NY) at
360mA for 1hour. Upon completion of the transfer the blotting membrane was placed in a
blocking solution 0.5% milk solution and incubated for 1 hour to overnight at 4°C in order
to prevent non‐specific binding of primary and/or secondary antibodies to the membrane.
(When removing the blotting membrane from the “blotting sandwich”, it is important to
pay attention to the orientation of the membrane or mark a corner so that the proteins can
be correctly imaged and identified.) After incubation in the blocking solution the transfer
membrane was washed 3 times for 10 minutes each in 50mM tris‐Buffered Saline with 1%
Tween20 (TBST). After washing, the membrane was incubated in 50ml TBST and 50µl of
primary antibody, Anti‐Flagellin (FliC) (Invivogen, San Diego, CA) for 1 hour, shaking at
room temperature. Following incubation with the primary antibody, the membrane was
washed 3 times for 10 minutes each in 50ml TBST. The membrane was then incubated in
50ml TBST and the secondary antibody, Rat anti‐mouse IgG horseradish peroxidase (HRP)
(Southern Biotech, Birmingham, AL) for 1 hour, shaking at room temperature. After
incubation the membrane was again washed 3 times in 50ml TBST for 10 minutes each.
The membrane was imaged using Western Lightning® Plus‐ECL, Enhanced
Chemiluminescence Substrate (Perkin Elmer, Walthan, MA) and the ImageQuant™ LAS
4000 (GE Lifesciences, Piscataway, NJ).
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Figure 12. Set up for Western Blotting using
Xcell II Blot Module.
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3. RESULTS
3.1. Optimization of polyethylene glycol 3350 precipitation of soluble
recombinant FA4000 and 5088 proteins
Several different concentrations of polyethylene glycol 3350 (PEG 3350) were
evaluated to determine the most efficient concentration to precipitate FA4000 and 5088
recombinant proteins following homogenization and initial centrifugation. FA4000 protein
was precipitated with a 4%, 6%, 9%, and 12% concentration of PEG 3350 and the 5088
protein with a 4%, 6%, 9%, 12%, and 15% concentration to determine which
concentration precipitated the greatest amount of FA4000 and 5088 protein, in addition to
removing a significant amount of the contaminating protein. Using SDS‐PAGE and
Coomassie® Blue staining to visually evaluate the results, a 4% (w/v) concentration of PEG
3350 yielded the best results for precipitation of both FA4000 and 5088. The recombinant
proteins can clearly be seen in both the resuspended PEG 3350 pellet and refined lysate
(RL) for FA4000 (Figure 12) and in the RL for 5088 (Figure 13). For 5088, a second band
just below the recombinant protein was precipitated out at concentrations higher than 6%
PEG 3350 making it appear that more recombinant protein had been precipitated. There
was some loss of FA4000 and 5088 in the PEG 3350 supernatant, but the amount was not
significant. Concentrations greater than 4% PEG 3350 did not increase the amount of
recombinant protein present in either the resuspended PEG 3350 pellet or the RL for either
FA4000 or 5088. A lower concentration of 2% PEG 3350 was also evaluated, but the pellet
was too small for efficient processing.
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B.

Figure 13. SDS‐PAGE of FA4000 protein precipitated using different concentrations
of PEG 3350 during purification The highlighted areas indicate the location of the
putative FA4000 protein. A. 6%, 9% and 12% PEG 3350 precipitation. Lanes 9‐11 show
putative FA4000 protein present in 6%, 9% and 12% resuspended PEG pellet. Lanes 12‐
14 show putative FA4000 protein present in 6%, 9%, and 12% refined lysate. B. 4%
PEG 3350 precipitation. Lanes 2 & 3 show putative FA4000 protein present in 4%
resuspended PEG pellet and refined lysate, respectively.
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A.

B.

Figure 14. SDS‐PAGE of 5088 protein precipitated using different concentrations
of PEG 3350 during purification The highlighted areas indicate the location of the
putative 5088 protein A. 6%, 9%, 12% and 15% PEG 3350 precipitation. Lanes 12‐
14 show presence of putative 5088 protein in refined lysate. B. 4% PEG 3350
precipitation. Lanes 2 & 3 show presence of putative 5088 protein in 4%
resuspended PEG pellet and refined lysate, respectively.
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3.2. Purification of soluble FA4000 and 5088 recombinant proteins

Each step of the purification process was designed to remove a specific or several
impurities in order to obtain an acceptable level of purity in the protein. Samples were
taken at designated steps in the process to determine the presence of the target protein
using SDS‐PAGE and protein purity (Appendix B) and the results determined whether to
continue to the next purification step. Following homogenization, initial centrifugation
and precipitation of the recombinant proteins using a concentration of 4% PEG 3350, the
putative FA4000 and 5088 proteins can be seen in the refined lysate (RL), aqueous phase
(AP) and filtered aqueous phase (FAP) samples run on SDS‐PAGE and stained with
Coomassie® Blue (Figures 14 & 15). There was also a significant reduction of
contaminating proteins and increase in the relative amount of FA4000 and 5088 protein
present in the samples. Following the 2‐phase separation, the endotoxin level of the AP
was reduced from 107 EU/ml in the cell lysate to 103 EU/ml for both FA4000 and 5088.
Some loss of FA4000 and 5088 proteins was seen in the PEG 3350 supernantant and RL
pellet, but this was expected during processing especially in centrifugation steps.
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Figure 15. SDS‐PAGE of putative FA4000 protein purification samples taken
through two‐phase separation step. The highlighted area indicates the location of
putative FA4000 seen in the resuspended PEG 3350 pellet (lane 7), RL (lane 8)
AP (lane 11) and FAP (lane 12).
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Figure 16. SDS‐PAGE of putative 5088 protein purification samples taken through
2‐phase separation step. The highlighted area indicates the location of putative
5088 protein seen in the resupended PEG 3350 pellet (lane 6), RL (lane 7), AP
(lane 10) and FAP (lane 11).
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Following the 2‐phase separation, the FAP was loaded onto a Toyopearl® PPG‐600
HIC column (Tosoh Bioscience, King of Prussia, PA) and decreasing the salt concentration
of the buffer running through the column eluted the bound protein. The fractions
corresponding to each protein peak indicated by a peak in the UV280 were collected, run on
a SDS‐PAGE gel and stained with Coomassie® blue. SDS‐PAGE results showed the putative
FA4000 protein (approximately 55kDa) in fractions A8 and A9 corresponding to peak 2 on
the HIC chromatogram (Figures 16 and 17). Fractions A8 and A9 were chosen for further
evaluation and validation due to their purity seen in SDS‐PAGE. The putative 5088 protein
(approximately 52kDa) was present in in fractions A1 and A2 corresponding to peak 1 on
the HIC chromatogram (Figure 18 & 19). These two fractions were selected based on their
purity seen in SDS‐PAGE for further processing and validation of recombinant 5088
protein. The recombinant protein yield for both FA4000 and 5088 from HIC was 12‐15%.
The endotoxin levels for FA4000 and 5088 following HIC were reduced to 101‐102 EU/ml
and 102 EU/ml, respectively from 103 EU/ml in the FAP.
The final yield of purified FA4000 was 450mg‐680mg protein and 380mg‐600mg
protein for 5088 from a 30L fermentation. The endotoxin levels were significantly
reduced during the purification process, with the greatest decreases in endotoxin seen in
the 2‐phase separation step and HIC separation (Table 4) bringing ET to a 150EU/mg
protein for FA4000 and 175EU/mg protein for 5088, a level acceptable for use as a vaccine.
Protein concentrations for samples taken throughout the purification process are shown in
Table 5.
Western Blot was used to confirm the presence of recombinant FliC in the FA4000
and 5088 proteins selected following HIC. Using a commercially available anti‐flagellin
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FliC, the Western Blot showed the presence of FliC in FA4000 fractions, A8 and A9, as well
as fraction A1 for 5088 (Figure 20). FA4000 and 5088 were also identified as flagellin
from Salmonella enterica and Salmonella typhimurium, respectively, by mass
spectrophotometry (MALDI TOF/TOF) (Appendix C). Salmonella typhimurium is a
subspecies of S. enterica.

Figure 17. SDS‐PAGE of hydrophobic interaction chromatograpy fractions for
recombinant FA4000 protein. The highlighted area indicates the location of putative
purified FA4000 protein in fractions A8 and A9 (lanes 8 and 9, respectively).
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FA4000

Figure 18. Chromatogram for hydrophobic interaction chromatography of recombinant
FA4000 protein. Putative purified FA4000 protein was present in the second UV280
peak following the loading step (fractions A8 and A9).
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Figure 19. SDS‐PAGE of hydrophobic interaction chromatography fractions for
recombinant 5088 protein. The highlighted area indicates the location of putative
purified 5088 protein in fractions A1 and A2 (lanes 5 and 6, respectively).
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5088

Figure 20. Chromatogram for hydrophobic interaction chromatography of recombinant
5088 protein. Putative purified 5088 protein was present in the first UV280 peak
following the loading step (fractions A1 and A2).
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Table 4. Endotoxin levels of FA4000 and 5088 protein samples
taken throughout the purification process.
Sample
FA4000 endotoxin
5088 endotoxin
(EU/ml)
(EU/ml)
Cell lysate
2x108
1.3x108
6
Refined lysate
1.5x10
5.1x107
Filtered aqueous 2.5x103 – 2x104
3.3x103
phase
HIC fractions
36‐170
106
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Table 5. Total protein concentrations for FA4000 and 5088
recombinant protein samples taken during purification process.

Sample
cell lysate
preliminary spin
supernatant
preliminary spin pellet
PEG supernatant
resuspended PEG pellet
Refined lysate
Refined lysate pellet
Aqueous phase
Detergent phase
HIC fractions

FA4000 total
protein
concentration
(mg/ml)
13.9‐18.3

5088 total
protein
concentration
(mg/ml)
15‐17

11.4‐12.8
2.9‐4
10.6‐11.4
0.9‐1.6
0.6‐1.3
0.5‐0.7
0.6‐1
0.4‐0.5
0.12‐0.18

10.8‐12.5
1.7‐6.2
9.2‐10.8
1.2‐5.2
0.6‐4.4
1.1‐1.9
0.5‐3.8
0.3‐0.7
0.13‐0.16
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1
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3

4

5

6

Figure 21. Image of Western Blot for detection of recombinant FliC. Lane 1 and 2,
containing FA4000 fractions A8 and A9 respectively, and Lane 3, containing 5088,
show the presence of FliC. Lanes 4‐6 contain FA4000 purification samples from cells
where induction of the FA4000 protein was low.
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3.3. TLR5 Activity of purified recombinant FA4000 and 5088 proteins

Following the identification of FA4000 and 5088 proteins via Western Blot and
mass spectrophotometry, the samples were tested for TLR5 activity to determine if the
proteins were biologically active and able to induce an innate immune response.
Preliminary results for the FA4000 and 5088 samples eluted directly from the HIC column
showed either no TLR5 activity or lower activity than the positive control, commercially
available recombinant S. typhimurium FliC (Figures 21A & B). The low TLR5 activity was
determined to be due to the presence of high residual salt from the HIC separation. The
high salt levels inhibited the growth of the HEK cells used in the TLR5 assay. The samples
were desalted using a dextran desalting column (Pierce, Rockford, IL and GE Lifesciences,
Piscataway, NJ). Figure 22 shows a typical desalting chromatogram, with the UV280 peak
indicating the protein has eluted followed by a separate peak in conductivity indicating the
salt has eluted separately from the protein. The presence of FA4000 (Figure 23A & B) and
5088 (Figure 24) in fractions collected from the desalting column were confirmed using
SDS‐PAGE and silver staining to image the protein. Following desalting, the samples
containing FA4000 and 5088 were re‐tested for TLR5 activity and a significant increase in
TLR5 activity was observed with the desalted protein (Figures 21b & 23b). TLR5 activity
for FA4000 fraction A8 increased from 0% activity to 98% and fraction A9 increased from
58% activity to 97% (% activity was calculated using the activity of recombinant FliC as
100% activity). 5088 TLR5 activity increased from 0% activity to 115% activity in fraction
A1 and 56% activity to 93% activity in fraction A2. The results indicate that the purified
FA4000 and 5088 proteins are biologically active and capable of inducing an innate
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immune response via TLR5. With the addition of a desalting step to the purification, the
final purification scheme for soluble recombinant FA4000 and 5088 proteins is shown in
Figure 27.
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A.

B.

Figure 22. TLR5 activity of purified FA4000 and 5088 proteins
following hydrophobic interaction chromatography A)TLR5
activity of purified FA4000, fractions A8 and A9 from HIC
separation. B) TLR5 activity of purified 5088, fractions A1 and A2
from HIC separation.
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Protein

Salt

Figure 23. Chromatogram for protein desalting. The recombinant protein was
present in fractions A3 and A4 indicated by a peak in the UV280. The salt eluted
later as indicated by a peak in the conductivity.
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A.

!!

B.

Figure 24. SDS‐PAGE of FA4000 fractions collected from a desalting column. A) Silver
stained SDS‐PAGE of fraction A8 collected in 500µl fractions from 10ml desalting
column. B) Silver stained SDS‐PAGE gel of fraction A9 collected in 500µl fractions from
10ml desalting column. Highlighted areas indicate the location of the recombinant
FA4000 protein.
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Figure 25. SDS‐PAGE of 5088 fractions collected from a desalting column. Silver stained
SDS‐PAGE of 5088 fraction A1 and desalted 5088 protein in lanes 12‐14. Highlighted area
indicates the location of the recombinant 5088 protein. The protein bands are white due to
overloading the gel.
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Figure 26. . TLR5 activity of purified FA4000 and 5088 proteins
following removal of residual salt from hydrophobic interaction
chromatography. A) TLR5 activity for recombinant FA4000
protein in fraction A8 and A9 following a desalting step. B) TLR5
activity for recombinant 5088 protein in fractions A1 and A2
following a desalting step.
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Figure 27. Purification strategy for soluble recombinant FliC constructs overexpressed in E.
coli.
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3.4. Comparison of TLR5 Activity for soluble recombinant protein and refolded
recombinant protein

The TLR5 activity of purified soluble FA4000 and 5088 proteins was compared to
the TLR5 activity of recombinant proteins that had been previously purified at GSU using a
denaturing and refolding step. The TLR5 assay results showed that the soluble
recombinant protein purified without using a denaturing and refolding step had a much
higher TLR5 activity than recombinant protein that had been denatured and refolded
(Figure 27). When compared to the TLR5 activity of the commercially available
recombinant FliC standard, the TLR5 activity of recombinant protein that was denatured
and refolded had 60‐62% activity and soluble protein had 105‐110% TLR5 activity. (%
activity was calculated using the activity of recombinant FliC standard as 100% activity)
The amount of refolded protein necessary to elicit a TLR5 response was also significantly
higher than the amount of soluble protein. When compared to the recombinant FliC
standard, the refolded protein required 35‐700x the amount of protein to elicit a TLR5
response much lower than the FliC standard while the soluble protein required only 1.5‐
7.5x the amount of protein to elicit a TLR5 response comparable to the FliC standard (Table
7). Overall, these results indicate that soluble protein was more effective in inducing an
innate immune response via TLR5 than recombinant protein that has been refolded.
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TLR5 activity of Refolded and
Soluble protein
2.5
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1.5
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Soluble
wlagellin
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Figure 28. Comparison of TLR5 activity for refolded flagellin and
5088 proteins and soluble flagellin and 5088 proteins.

Table 6. TLR5 percent activity and protein concentrations of
refolded and soluble proteins
Sample
% Activity
Protein
concentration
Recombinant FliC
100
0.2µg
Standard
Refolded Flagellin
62
7µg
construct
Refolded 5088
60
140µg
Soluble FA4000
110
0.4‐1.5µg
Soluble 5088
105
0.3‐1µg
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3.5. Stability of Recombinant FA4000 and 5088 recombinant protein at 4°C

Because the purified recombinant proteins are to be used as potential vaccines, it is
important that they can be stored for a significant amount of time without losing their
efficacy. Purified FA4000 and 5088 were stored at 4°C for a 6‐month period and the TLR5
activity was tested to determine whether bioactivity was maintained during storage. Both
the FA4000 and 5088 protein sustained TLR5 activity comparable to their initial activity
following purification (Tables 8 & 9).

Table 7. TLR5 activity of FA4000 fractions A8 and A9 after 6 months of storage at
4°C. Chart shows % of TLR5 activity with positive control equal to 100% TLR5
activity.
Sample
% TLR5 activity
Fraction A8
97
Fraction A8 (stored at 4°C)
125
Fraction A9
95
Fraction A9 (stored at 4°C)
110

Table 8. TLR5 activity of 5088 fractions A1 and A2 after 6 months of storage at 4°C.
Chart shows % of TLR5 activity with positive control equal to 100% TLR5 activity.
Sample
Fraction A1
Fraction A1(stored at 4°C)
Fraction A2
Fraction A2(stored at 4°C)

% TLR5 activity
104
115
105
93
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4. DISCUSSION

In this study, purification of tag‐less soluble recombinant full‐length Salmonella
typhimurium FliC flagellin (FA4000) and Salmonella typhimurium FliC flagellin with a
Marberg virus antigen (GP132) linked at the C‐terminal end (5088) proteins expressed in
E. coli to vaccine standards was achieved utilizing well‐established techniques that take
advantage of the physical and chemical properties of the protein. The techniques and
methods were appropriate for large‐scale vaccine production and yielded enough
recombinant protein for approximately 75,000‐120,000 doses of vaccine in a single 30L
fermentation. Previous research has shown protective immunity using flagellin fusion
proteins in mice with doses as low as 1‐3µg of recombinant protein (Honko et al., 2006;
Song et al., 2008). Assuming a vaccine dose of 5μg, the endotoxin present in the vaccine
would be 0.18‐0.85EU/dose for FA4000 and 0.53EU/dose for 5088. Using the criteria of
5EU/kg bodyweight, the purified proteins fall well under this limit.
Using a purification strategy designed for only the soluble protein without steps to
recover the insoluble protein, the time and potential cost necessary for purification were
significantly reduced, primarily due to the removal of the tangential flow filtration,
denaturing and refolding steps (Figure 28). The process of refolding recombinant protein
into a biologically active molecule alone can account for a large portion of time and cost
involved in commercial protein production (Datar et al., 1993). It was also hypothesized
that by purifying the soluble protein without a denaturing and refolding step, the TLR5
activity for purified soluble recombinant protein would have a higher activity than
recombinant protein that had been purified using denaturing and refolding steps. Soluble
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protein that was purified using non‐denaturing conditions and no refolding step, showed
TLR5 activity comparable to 200ng of commercially available recombinant flagellin from S.
typhimurium and required no more than 7.5x the amount of protein compared to the
positive control. Protein purified using a refolding step showed TLR5 activity lower than
the positive control for both recombinant 5088 and flagellin proteins and required 35x
more protein for purified flagellin and 700x more protein for 5088 when compared to the
amount of protein used as a positive control. This result was not surprising as typical
yields of bioactive protein following protein refolding ranges from 15‐40%, primarily due
to protein aggregation during refolding (Singh and Panda, 2005; Yang et al., 2011).
Overall, the purification scheme used was effective in purifying both FA4000 and
5088 recombinant proteins to vaccine standards. However, some of the recombinant
FA4000 and 5088 protein was lost during steps in purification, but this was expected as
each purification step usually results in some protein loss and not all of the protein can be
recovered without also picking up contaminants, especially during steps involving
centrifugation. There was a significant loss of protein in the HIC step. A 10‐15% protein
yield was low, and both FA4000 and especially 5088 can be seen in the fractions that were
not evaluated for this study. Future studies should address ways to increase the protein
yield coming off of the HIC column by evaluating other types of HIC media and/or types of
salt and salt concentrations used to dilute the protein prior to HIC.
While both FA4000 and 5088 proteins were purified using the same purification
scheme there were notable differences with 5088. Hydrophobic interaction
chromatography (HIC) was not as efficient in purifying 5088. There was 5088 protein lost
in the column wash following the loading step, suggesting that some of the 5088 protein
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did not bind well to the HIC column. In addition, there was also 5088 protein present in
other protein peaks/fractions, which suggests the presence of 5088‐dimer protein. The
fractions from HIC also contained a higher level of contaminating protein indicating that
HIC was not as efficient in separating 5088 protein from other contaminating proteins.
5088 also eluted earlier than FA4000 during the step gradient indicating that it is not as
hydrophobic as FA4000, in spite of the fact that the protein sequences are very similar.
Future studies should include the implementation of analytical testing to further
characterize the recombinant flagellin (FliC) proteins.
Prior to utilizing HIC, anion exchange chromatography was evaluated for both
FA4000 and 5088 using a strong anion exchange column, Toyopearl® Super Q 650M. The
theoretical pI for FA4000 was 4.79 and for 5088 was 4.7 indicating that the overall protein
charge at a pH of 8 would be negative which would make AEX suitable for use with the
protein. However, neither protein bound efficiently to the AEX column and a majority of
the recombinant protein passed through the column without binding to the media and was
present in the load flow through. This might be due to endotoxin present in the sample. It
is suggested that future experiments be conducted which evaluate an additional 2‐phase
separation to remove more endotoxin prior to AEX or performing the 2‐phase separation
before the PEG precipitation to improve binding of the target protein to the column. If
anion exchange chromatography could be used instead of hydrophobic interaction, a
desalting step wouldn’t be necessary for purification, further reducing the purification time
of the soluble protein.
The TLR5 activity of both FA4000 and 5088 samples tested following HIC were
either much lower than expected or there was no activity at all. It was believed that the salt
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concentration of the eluted protein was too high for TLR5 activity to be tested using the
HEK‐Blue™ TLR5 cells. A desalting step was evaluated to determine if the high salt
concentration was interfering with the TLR5 assay. After desalting the samples using a
HiPrep™ 26/10 desalting column, a significant increase in TLR5 activity was seen in all
samples, confirming that the salt concentration following HIC was interfering with the
HEK‐Blue™ hTLR5 and null cells used for the TLR5 assay. A dextran column was chosen
for desalting rather than dialysis because: 1) it is a much faster process and 2) can be
scaled up for larger volumes by linking columns together in sequence, but can still be
limiting for very large volumes. For much larger volumes it may be necessary to add a
buffer exchange step using tangential flow filtration (TFF).
At present, most recombinant proteins containing flagellin are purified from
insoluble protein or, if expressed as soluble protein, are usually his‐tagged for ease of
purification (Mizel and Bates, 2010). The results of this study indicate that recombinant
FliC proteins expressed as soluble protein during a fermentation can be purified in an
efficient and cost effective manner without the use of a tag and the purified soluble
proteins exhibit a much higher TLR5 activity at a lower protein concentration than
recombinant proteins that have been subjected to refolding. However, how recombinant
proteins are expressed during fermentation is highly protein sequence dependent,
suggesting that each recombinant protein will express differently, regardless of measures
to push expression toward soluble protein (Basu et al., 2011). Currently, recombinant
proteins expressed as inclusion bodies have been the most widely used for the commercial
use of proteins (Walsh, 2003). This is due to the fact that most recombinant proteins,
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approximately 70%, overexpressed in E. coli are insoluble protein (Yang et al., 2011). In
order to optimize the yield of recombinant protein it is important to develop purification
schemes that address both soluble and insoluble protein expression. While the
purification of insoluble proteins may be easier with respect to removal of contaminants,
refolding the protein into a bioactive molecule can often be time consuming and expensive.
The insoluble protein must first be completely solubilized and then refolded into a
biologically active protein creating a potential bottleneck in the purification process and
this process often accounts for a major portion of the cost during production as there is no
standardized method for refolding proteins. Even if future recombinant flagellin proteins
are expressed primarily as insoluble, the purification scheme developed in this study could
be used as a guide for purifying the soluble recombinant flagellin protein also present.
Once purified, the TLR5 activity could be assayed to determine if the recombinant protein
is biologically active while the solubilization and refolding of the insoluble protein is being
optimized. Purification of the soluble recombinant flagellin protein in order to determine
TLR5 activity could also prevent the investment of time and money into refolding the
insoluble protein if the end product does not elicit an innate immune response via TLR5.
This is especially important in recombinant flagellin proteins where portions of the native
protein are being deleted and/or antigen is being inserted, as the deletions and/or
insertions may effect the folding of the protein and its ability to induce a TRL5 immune
response.
The hypotheses stated in the introduction were supported by this study.
Both soluble recombinant FA4000 and 5088 were purified in less time and using fewer
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steps than previously used in purification method A (Figure 10) that utilized a denaturing
and refolding step to include both soluble and insoluble protein. The purified soluble
recombinant proteins, FA4000 and 5088, also exhibited a much higher TLR5 activity at a
lower concentration than recombinant proteins that had been refolded.
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7. APPENDICES
Appendix A. Detailed Laboratory Protocols
Homogenization
1. Thawing and Preparing Cells
a. Remove cells from ‐80C freezer and record name of construct, fermentation date
and amount of cell paste (g).
b. Place cells in 4°C refrigerator and allow to thaw overnight.
c. Retrieve thawed cells and chilled lysis buffer from 4°C refrigerator.
d. Calculate amount of lysis buffer needed to resuspend cell paste.
Weight of cell paste (g)/0.15 = amount of lysis buffer (ml)
e. Add a small amount of lysis buffer and stir bar to an appropriately sized
container and then slowly pour thawed cells into the lysis buffer while stirring.
f. Rinse remaining cells from bottle using lysis buffer and add to container to be
used for resuspending the cells.
g. Add remaining amount of lysis buffer to container.
h. Mix on stir plate for at least 20 minutes. Keep resuspended cells cold in an ice
bath while stirring.
2. Prepare the APV‐1000 homogenizer
a. While the cells are being resuspended, replace water in recirculating cooling
loop with fresh cold ddH2O and begin pumping (set flow to 50‐100ml/min).
b. Fill hopper with 1.5L chilled ddH2O and recirculate through APV for ≥ 10min and
then drain.
c. Fill hopper with 500ml chilled lysis buffer and recirculate through APV for ≥
10min, drain and discard lysis buffer.
d. Place container(s) for receiving homogenized cells into ice bath prior to
beginning homogenization.
3. Homogenization
a. Sample re‐suspended cells (2x1ml sample).
b. Load re‐suspended cells into hopper. Homogenize for 1 pass through
homogenizer at 0bar. Cool sample to 5‐7°C before next pass in homogenizer
c. Homogenize sample for 3 more passes at 690 bar allowing the temperature to
cool to 5‐7°C prior to next pass. Monitor the temperature of the cell lysate aas it
leaves the homogenizer making sure the temperature of lysate stays below 24C
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d. After the final pass, sample the cell lysate (2x1ml) and record the final weight
and volume.
e. If not processed immediately, store at 4°C.
4. Clean the Homogenizer
a.
b.
c.
d.
e.
f.

Fill the hopper with 2L ddH2O.
Run through the homogenizer and discard.
Fill the hopper with 2L fresh ddH2O and recirculate for at least 10 minutes.
Drain from homogenizer and discard.
Fill hopper with 0.1N NaOH and recirculate for 10 minutes.
Drain from homogenizer and discard.

Clarification by Centrifugation
1. Turn on centrifuge and set temperature to 4°C.
2. Aliquot equal volumes of lysate into centrifuge bottles and weigh each bottle to
ensure that the centrifuge is balanced.
3. Load into centrifuge and spin for 1h @10,000rpm.
4. After centrifugation, collect supernatant via pipetting (pellet will be loose).
5. Pool the supernatants and measure total weight and volume.
6. Take sample of the pooled supernatant (2 x 1ml)
7. Pool pellets and weigh. Resuspend in Pellet Resuspension buffer equal to volume of
supernatant. (May sample a smaller amount of the pellet and add equivalent
amount of Pellet Resuspension Buffer)
8. Discard the pellet.

Polyethylene Glycol 3350 Protein Precipitation
1. Determine the amount of PEG 3350 needed for precipitation.
Amount of PEG 3350 to add= pooled supernatant volume (ml)*0.04 (4%)
2. Weigh out required amount of PEG 3350.
3. Slowly add the PEG 3350 to the pooled supernatant while stirring.
4. Once all of the PEG 3350 has been added and dissolved, allow to stir for ≥ 15
minutes.
5. Aliquot equal volumes of the pooled supernatant into centrifuge bottles and weigh
each bottle to ensure that the centrifuge is balanced.
6. Load into centrifuge and spin for 1h @10,000rpm, 4°C.
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7. After centrifugation, collect supernatant via pipetting or gently pouring
Measure volume of supernatant, sample (2 x 1ml) and discard.
If not processed immediately, the PEG pellets can be stored at ‐20°C.
Pellet Resuspension and Centrifugation
1. Resuspend pooled PEG pellets in Resuspension Buffer (half the volume of the
supernatant from previous centrifugation)
2. Disrupt pellets mechanically using a disposable inoculation needle.
3. Mix pellets with a stir bar until the pellet has been completely resuspended.
4. Sample the resuspended pellet (2x1ml).
8. Aliquot equal volumes of the resupended pellet into centrifuge bottles and weigh
each bottle to ensure that the centrifuge is balanced.
9. Load into centrifuge and spin for 1h @10,000rpm, 4°C.
10. After centrifugation collect supernatant via pipet, pool supernatants and record
total volume and weight. Collect 2x1ml samples. This is the “refined lysate.”
11. If not processed immediately, store Refined lysate at 4°C.
12. Pool pellets and record weight. Resuspend in Pellet Resuspension buffer equal to
volume of the Refined lysate (May sample a smaller amount of the pellet and add
equivalent amount of Pellet Resuspension Buffer).
13. Discard the pellet
2‐phase separation
1. Calculate the amount of Triton® X‐114 (1% (w/w) to add to Refined lysate.
Weight of Refined lysate (mg)*0.01= amount of Triton X®‐114 to add
2. Add calculated amount of Triton X®‐114 to Refined lysate
3. Stir for 30 minutes.
4. Aliquot equal volumes of the Refined lysate into centrifuge tubes and weigh each
tube to ensure that the centrifuge is balanced.
5. Centrifuge for 4h @ 10000rpm, 24°C (Decel set to 0). Sample can be left overnight
in centrifuge.
6. Carefully retrieve the samples from the centrifuge.
7. Gently pipet off the top layer (aqueous phase) of the 2‐phase separation.
8. Pool the aqueous phase from each centrifuge tube and record the total volume.
Sample the aqueous phase (2 x 1ml).
9. Filter using a 0.2
10. If not immediately processed, store at 4°C.
11. Pool the bottom layer (detergent phase), record volume, sample (2 x 1ml) and
discard.
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Lysis Buffer ‐ 20mM Tris, 100mM NaCL, 1mM EDTA, 100mM sucrose, pH 8 (1L)
Add 750ml ddH2O to a 1L bottle with a stir bar.
Add 34.2g of sucrose.
Add 2.42g of tris
Add 5.82g of NaCl
Add 372mg of EDTA
Stir until completely dissolved.
Adjust pH using Acetic Acid
QS to 1L with ddH2O.
Filter sterilize, (0.2 µm filter unit).
Store at 4°C

•
•
•
•
•
•
•
•
•
•

Resuspension Buffer ‐ 20mM Tris, 1mM EDTA, 100mM sucrose, pH 8 (1L)
Add 800 ml ddH2O to a 1L bottle with a stir bar
Add 2.42g of Tris
Add 372mg of EDTA
Add 34.2g of sucrose
Stir until completely dissolved
Adjust pH using acetic acid
QS to 1L with ddH2O.
Filter sterilize, (0.2 µm filter unit)
Store at 4°C

•
•
•
•
•
•
•
•
•

Pellet Resuspension Buffer – 20mM tris, 8M urea, pH 8
•
•
•
•
•
•
•
•
•

Add 500ml ddH2O to a 1L bottle with a stir bar.
Gradually add 480.48g of Urea.
Stir until completely dissolved.
Add 2.42g of Tris.
Stir until completely dissolved.
Adjust pH to 8 with acetic acid.
Make up to 1L with ddH2O ..
Filter sterilize, (0.22um CA or PES filter unit)
Store at room temperature
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Hydrophobic Interaction Chromatography
1. Sample preparation
a. Calculate volume of sample containing 15mg total protein and add to 250ml
container.
b. While stirring, slowly add an equal volume of Dilution Buffer (20mM tris, 5M
NaCl, pH8) and allow to stir for at least 10 minutes following addition of Dilution
Buffer.
c. Filter samples using a 0.2µm PES syringe filter.
d. Dilute sample prior to loading onto column to a final protein concentration of
0.2mg/ml with Elution Buffer (20mM tris, 2.5M NaCl, pH 8).
2. ÄKTAexplorer™100 preparation
a. Prior to beginning HIC program, prime the system buffer lines to be used for the
program.
b. Prime the sample line, S1, with equilibration buffer and leave the line in
equilibration buffer until just before the program is started.
c. Remove pH meter from storage buffer and rinse with ddH2O. Remove “dummy”
pH meter and replace with pH meter.
3. Hydrophobic Interaction Chromatography
(Chromatography was performed using the ÄKTAexplorer™100 system and
UNICORN 5.01 control software (GE Lifesciences, Piscataway, NJ) and the method
created using Method Wizard.)
Flow rate for program was 5ml/min
a. Place Equilibration Buffer/Elution Buffer 1 on Buffer line assigned during the
Method Wizard set up. (Buffer line A11‐ A18)
b. Place Equilibration Buffer 2 on Buffer line B1.
c. Equilibrate column with 8CV of Equilibration Buffer (20mM tris, 2.5M NaCl, pH
8).
d. Load 10mg (50ml) of protein onto HIC column. Manually collect load flow
through from Outlet line F3 in a 50ml centrifuge tube.
e. Wash column with 2CV of Equilibration Buffer (20mM tris, 2.5M NaCl, pH 8)once
all protein has been loaded to the column. Manually collect flow through from
Outlet line F3 in a 15ml centrifuge tube.
f. Elute bound protein with a step gradient of 25%, 50%, 75% and 100% Elution
Buffer 2 (20mM tris, pH 8). Collect in 5ml fractions using Frac‐950, outlet F2.
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Dilution Buffer – 5M NaCl, 20mM tris, pH 8 (1L)
•
•
•
•
•
•
•
•

Add 700ml ddH2O to a 1L bottle with a stir bar
Add 292.2g NaCl
Add 2.42g tris
Stir for ≥ 10 min
Adjust pH using acetic acid
QS to 1L with ddH2O.
Filter sterilize, (0.2 µm filter unit)
Store at room temp

Equilibration Buffer/Elution buffer 1– 2.5M NaCl, 20mM tris, pH 8 (1L)
•
•
•
•
•
•
•
•

Add 700ml ddH2O to a 1L bottle with a stir bar
Add 146.1g NaCl
Add 2.42g tris
Stir for ≥ 10 min
Adjust pH using acetic acid
QS to 1L with ddH2O.
Filter sterilize, (0.2 µm filter unit)
Store at room temp

Elution Buffer 2 ‐ 20mM Tris, pH 8.0 (1L)
•
•
•
•
•
•
•

Add 900 ml ddH2O to a 1L bottle with a stir bar
Add 2.42g of Tris
Stir for ≥ 10 min
Adjust pH using acetic acid
QS to 1L with ddH2O.
Filter sterilize, (0.2 µm filter unit)
Store at room temp
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TLR5 Assay
Day 1
1. Prepare test medium (same as growth medium)
DMEM, 4.5g/l glucose
50ul/ml penicillin
50ug/ml streptomycin
100ug/ml Normocin,
2mM L‐glutamine
10% (v/v) heat‐inactivated FBS
2. Prepare cell suspension of HEK‐blue‐hTLR5 cells and null cells of ~140,000 cells/ml
in test medium
Counting HEK cells with Neubauer hemocytometer
a. Count the cells in the 4 large corner squares and the large middle
square (each large square is made up of 16 little squares)
b. Add the total cell count (must be >than 100 total)
c. Calculating cell #
(Total # cells counted/0.5mm3) (1000)(dilution factor) =
#cells/ml
3. Add 20ul of each sample per well of a flat bottom 96 well plate
4. Add 20ul of RecFLA‐ST (flagellin) in one well as a positive control and 20ul of
sterile, endotoxin free water in another well as a negative control
5. Add 180ul of cell suspension/well
6. Incubate plate at 37C in a CO2 incubator for 20‐24 hours.
Day 2
1.
2.
3.
4.

Prepare QUANTI‐Blue solution
Add 180ul of resuspended QUANTI‐Blue per well of a 96‐well plate.
Incubate the plate at 37C incubator for 1‐3h.
Determine SEAP levels using a spectrophotometer at 620‐655λ
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Reviving TLR5 cells from glycerol stock
1.
2.
3.
4.
5.
6.
7.

Before using the tissue culture hood, clean the hood with 70% ethanol.
Remove glycerol stocks from nitrogen storage and place in 37°C water bath to
thaw.
While glycerol stocks are thawing, add required amount of growth media w/o
antibiotics to tissue culture flask, place in CO2 incubator and allow to warm media
When glycerol stocks have thawed remove glycerol stocks from water bath and
ethanol the cryovials before placing in the hood.
Remove the growth media from the CO2 incubator, ethanol and place in the hood.
Add HEK cells (hTLR5 and Null) to the tissue culture flasks containing growth media
and label flasks.
Place in 37°C, 5% CO2 incubator

Growth media for HEK hTLR5 and Null cells (w/o antibiotics)
•
•
•
•
•

Remove 58.5ml of media from DMEM with 4.5g/L NaCl (Corning, Tewksbury, MA)
Add 50ml Heat inactivated Fetal Bovine Serum (Invitrogen, Grand Island, NY)
Add 2.5ml concentrated Penicillin/Streptomycin solution (Corning, Tewksbury, MA)
Add 5ml 200mM glutamine solution (Corning, Tewksbury, MA)
Add 1ml Normocin™ (50mg/ml, Invivogen, San Diego, CA)

Test media for hTLR5 cells (w/ antibiotics)
• Place 50ml of growth media w/o antibiotics into a 50ml falcon tube
• Add 50ul Zeocin™ (100mg/ml in HEPES buffer, Invivogen, San Diego, CA)
• Add 150ul Blasticidin (10mg/ml in HEPES buffer, Invivogen, San Diego, CA)
Test media for Null cells (w/ antibiotics)
•
•

Place 50ml of growth media without antibiotics into a 50ml falcon tube
Add 50ul of Zeocin™ (100mg/ml in HEPES buffer, Invivogen, San Diego, CA)
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Appendix B. Sampling and Testing Schedule

Process Step
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Homogenization Resuspended
cell paste
Homogenization lysate (final
pass)
Initial spin
pooled
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resuspended
pellet
PEG
pooled
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Refined Lysate
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Wash

x
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Appendix C. Mass Spectrophotometry Results
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